Commission of the European Communities "Europe Against Cancer" Programme European school of oncology advisory report cancer treatment in the elderly

S. Monfardini, M. Aapro, L. Ferrucci, V. Zagonel, P. Scalliet, I. Fentiman

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Within the EC approximately one million cases of cancer are diagnosed every year. At present, more than 55% of cancers occur in subjects aged over 65 years. There has been little clinical attention to the problem of neoplasia in the elderly. They are not receiving the same standard of specialised oncological care as younger patients. Other diseases (co-morbidity conditions) associated with cancer, and influencing its treatment and outcomes are not being properly considered. Information on surgery, radiotherapy and chemotherapy in younger patients exists for all cancers and could be adapted for the elderly. Controversial aspects of neoplasia in the elderly concern the intensity of chemotherapy, extent of surgery and the relative roles of specialised cancer centres, community hospitals and primary care providers. Future research should aim to replace subjective opinions on presence of frailty with objective instruments such as the multidimensional geriatric assessment scale. New trials could then seek to improve treatment in well-defined populations in terms of both efficacy and quality of life. Funding priorities should firstly consider that clinical trials for tumours in the elderly must be organised from cancer institutes and specialised referral centres in collaboration with geriatricians, primary care and community hospital physicians. Continuing education of doctors should be supported. A document such as this with appropriate modifications might be used as an initial message on neoplasia in the elderly to be published for information to clinicians and the public throughout Europe. Specific measures of quality assurance need financial support to evaluate the improvements in patterns of care. The 10 points of the 'Europe Against Cancer Guidelines' need reemphasising.

Original languageEnglish
Pages (from-to)2325-2330
Number of pages6
JournalEuropean Journal of Cancer
Volume29
Issue number16
Publication statusPublished - 1993

Fingerprint

European Union
Neoplasms
Therapeutics
Community Hospital
Primary Health Care
Geriatric Assessment
Financial Support
Drug Therapy
Continuing Education
Radiotherapy
Referral and Consultation
Quality of Life
Clinical Trials
Guidelines
Morbidity
Physicians

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Cancer Research

Cite this

Commission of the European Communities "Europe Against Cancer" Programme European school of oncology advisory report cancer treatment in the elderly. / Monfardini, S.; Aapro, M.; Ferrucci, L.; Zagonel, V.; Scalliet, P.; Fentiman, I.

In: European Journal of Cancer, Vol. 29, No. 16, 1993, p. 2325-2330.

Research output: Contribution to journalArticle

@article{05285ec7da7a4194994051d9736e1a0b,
title = "Commission of the European Communities {"}Europe Against Cancer{"} Programme European school of oncology advisory report cancer treatment in the elderly",
abstract = "Within the EC approximately one million cases of cancer are diagnosed every year. At present, more than 55{\%} of cancers occur in subjects aged over 65 years. There has been little clinical attention to the problem of neoplasia in the elderly. They are not receiving the same standard of specialised oncological care as younger patients. Other diseases (co-morbidity conditions) associated with cancer, and influencing its treatment and outcomes are not being properly considered. Information on surgery, radiotherapy and chemotherapy in younger patients exists for all cancers and could be adapted for the elderly. Controversial aspects of neoplasia in the elderly concern the intensity of chemotherapy, extent of surgery and the relative roles of specialised cancer centres, community hospitals and primary care providers. Future research should aim to replace subjective opinions on presence of frailty with objective instruments such as the multidimensional geriatric assessment scale. New trials could then seek to improve treatment in well-defined populations in terms of both efficacy and quality of life. Funding priorities should firstly consider that clinical trials for tumours in the elderly must be organised from cancer institutes and specialised referral centres in collaboration with geriatricians, primary care and community hospital physicians. Continuing education of doctors should be supported. A document such as this with appropriate modifications might be used as an initial message on neoplasia in the elderly to be published for information to clinicians and the public throughout Europe. Specific measures of quality assurance need financial support to evaluate the improvements in patterns of care. The 10 points of the 'Europe Against Cancer Guidelines' need reemphasising.",
author = "S. Monfardini and M. Aapro and L. Ferrucci and V. Zagonel and P. Scalliet and I. Fentiman",
year = "1993",
language = "English",
volume = "29",
pages = "2325--2330",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "16",

}

TY - JOUR

T1 - Commission of the European Communities "Europe Against Cancer" Programme European school of oncology advisory report cancer treatment in the elderly

AU - Monfardini, S.

AU - Aapro, M.

AU - Ferrucci, L.

AU - Zagonel, V.

AU - Scalliet, P.

AU - Fentiman, I.

PY - 1993

Y1 - 1993

N2 - Within the EC approximately one million cases of cancer are diagnosed every year. At present, more than 55% of cancers occur in subjects aged over 65 years. There has been little clinical attention to the problem of neoplasia in the elderly. They are not receiving the same standard of specialised oncological care as younger patients. Other diseases (co-morbidity conditions) associated with cancer, and influencing its treatment and outcomes are not being properly considered. Information on surgery, radiotherapy and chemotherapy in younger patients exists for all cancers and could be adapted for the elderly. Controversial aspects of neoplasia in the elderly concern the intensity of chemotherapy, extent of surgery and the relative roles of specialised cancer centres, community hospitals and primary care providers. Future research should aim to replace subjective opinions on presence of frailty with objective instruments such as the multidimensional geriatric assessment scale. New trials could then seek to improve treatment in well-defined populations in terms of both efficacy and quality of life. Funding priorities should firstly consider that clinical trials for tumours in the elderly must be organised from cancer institutes and specialised referral centres in collaboration with geriatricians, primary care and community hospital physicians. Continuing education of doctors should be supported. A document such as this with appropriate modifications might be used as an initial message on neoplasia in the elderly to be published for information to clinicians and the public throughout Europe. Specific measures of quality assurance need financial support to evaluate the improvements in patterns of care. The 10 points of the 'Europe Against Cancer Guidelines' need reemphasising.

AB - Within the EC approximately one million cases of cancer are diagnosed every year. At present, more than 55% of cancers occur in subjects aged over 65 years. There has been little clinical attention to the problem of neoplasia in the elderly. They are not receiving the same standard of specialised oncological care as younger patients. Other diseases (co-morbidity conditions) associated with cancer, and influencing its treatment and outcomes are not being properly considered. Information on surgery, radiotherapy and chemotherapy in younger patients exists for all cancers and could be adapted for the elderly. Controversial aspects of neoplasia in the elderly concern the intensity of chemotherapy, extent of surgery and the relative roles of specialised cancer centres, community hospitals and primary care providers. Future research should aim to replace subjective opinions on presence of frailty with objective instruments such as the multidimensional geriatric assessment scale. New trials could then seek to improve treatment in well-defined populations in terms of both efficacy and quality of life. Funding priorities should firstly consider that clinical trials for tumours in the elderly must be organised from cancer institutes and specialised referral centres in collaboration with geriatricians, primary care and community hospital physicians. Continuing education of doctors should be supported. A document such as this with appropriate modifications might be used as an initial message on neoplasia in the elderly to be published for information to clinicians and the public throughout Europe. Specific measures of quality assurance need financial support to evaluate the improvements in patterns of care. The 10 points of the 'Europe Against Cancer Guidelines' need reemphasising.

UR - http://www.scopus.com/inward/record.url?scp=0027731634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027731634&partnerID=8YFLogxK

M3 - Article

C2 - 8110505

AN - SCOPUS:0027731634

VL - 29

SP - 2325

EP - 2330

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 16

ER -